Huijuan Wang
- Hematology top 10%
- Multiple Myeloma Research and Treatments 14
-
- Peptidase Inhibition and Analysis 13
- Cancer-related Molecular Pathways 4
- Analytical Chemistry top 10%
- Orthopedics and Sports Medicine top 10%
-
- Ferroptosis and cancer prognosis 6
- Lung Cancer Treatments and Mutations 6
-
- Protein Degradation and Inhibitors 6
-
- Sepsis Diagnosis and Treatment 6
-
- Thyroid Cancer Diagnosis and Treatment 4
- Journals
- Journal of Clinical Oncology (3 papers)SHILAP Revista de lepidopterología (2 papers)Blood (4 papers)
- Partner nations
- ChinaUnited StatesFiji
In The Last Decade
Huijuan Wang
99 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 140
- Hematology 101
- Oncology 197
- Analytical Chemistry 64
- Orthopedics and Sports Medicine 55
- Immunology 118
Countries citing papers authored by Huijuan Wang
This map shows the geographic impact of Huijuan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huijuan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huijuan Wang more than expected).
Fields of papers citing papers by Huijuan Wang
This network shows the impact of papers produced by Huijuan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huijuan Wang. The network helps show where Huijuan Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Huijuan Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 19 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 3 | |
| 6 | 2024 | 5 | |
| 7 | 2024 | 5 | |
| 8 | 2024 | 3 | |
| 9 | 2023 | 11 | |
| 10 | 2023 | 0 | |
| 11 | 2023 | 1 | |
| 12 | 2023 | 1 | |
| 13 | 2022 | 0 | |
| 14 | 2022 | 15 | |
| 15 | 2022 | 2 | |
| 16 | 2022 | 48 | |
| 17 | 2022 | 1 | |
| 18 | 2021 | 17 | |
| 19 | 2020 | 6 | |
| 20 | 2014 | 4 |
About Huijuan Wang
Huijuan Wang is a scholar working on Oncology, Hematology and Critical Care and Intensive Care Medicine, having authored 112 papers that have together received 1.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Peptidase Inhibition and Analysis (13 papers), Ferroptosis and cancer prognosis (6 papers), Lung Cancer Treatments and Mutations (6 papers), Protein Degradation and Inhibitors (6 papers), Sepsis Diagnosis and Treatment (6 papers), Cancer-related Molecular Pathways (4 papers) and Thyroid Cancer Diagnosis and Treatment (4 papers). The work is most often cited by research in Hematology (101 citations), Oncology (197 citations) and Analytical Chemistry (64 citations). Huijuan Wang has collaborated with scholars based in China, United States and Fiji. Frequent co-authors include Ying Zhang, Guosheng Ding, Shiji Qin, Longxiang Su, Fengqi Zhang, Peng Yan, Haitao Zhao, Lihui Xu, Yaning Sun and Kun Xiao. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.